Chemotherapy sucks. It sucks because the patient suffers. We develop drugs that target only the cancer. We do this at a 50-fold reduced price point compared to our closest competitor.
Location: Austria, Lower Austria, Maria Gugging
Employees: 1-10
Total raised: $2.45M
Founded date: 2017
Investors 1
| Date | Name | Website |
| - | IST Cube | ist-cube.c... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 13.11.2023 | - | $2.45M | - |
Mentions in press and media 4
| Date | Title | Description |
| 05.06.2024 | VALANX Biotech announces promising results in first in-vivo study of novel protein conjugate therapy | Study demonstrates pre-clinical efficacy of lead program VLX101 in treating autoimmune disease Klosterneuburg, Austria - ALANX Biotech (VALANX), a biotech company developing novel technology for site-specific protein conjugation in drug and... |
| 13.11.2023 | Austrian VALANX Biotech announces fundraise of €2.3M | Austrian VALANX Biotech announces fundraise of €2.3M 13 November, 2023, 13:30 Mariia Denysiuk --> --> --> -->--> --> --> --> --> --> --> --> --> VALANX Biotech, a synthetic biology company, has anno... |
| 10.11.2023 | Austria-based VALANX Biotech bag €2.3M for drug development and diagnostics | Read this article in: Austria-based VALANX Biotech, a synthetic biology company, announced that it has secured €2.3M in a growth round of funding. In 2020, VALANX secured a six-figure seed investment from a syndicate including IST cube, tec... |
| - | VALANX Biotech | “Protein conjugation. Specific, fast and cost effective.” |